加载中
NASDAQHealthcareMedical - Instruments & Supplies
最新数据
US$2.06
+US$0.37 · +21.89%
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
收盘时
US$2.06
+US$0.37 · +21.89%
盘后
US$2.00
−US$0.06 · -2.91%
10月12日 19:51 ET
盘中时间采用ET。市场数据可能有所延迟。
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
日内区间
当前US$2.06
52周区间
当前US$2.06
盘中时间采用ET。市场数据可能有所延迟。
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
日内区间
当前US$2.06
52周区间
当前US$2.06
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（SGD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4.99万 SGD | 4.83万 SGD | 10.08万 SGD | 5.66万 SGD | 5.85万 SGD |
| 销货成本 | 5.05万 SGD | 5.13万 SGD | 6.42万 SGD | 3.66万 SGD | 3.54万 SGD |
| 毛利 | −645 SGD | −3024 SGD | 3.66万 SGD | 2万 SGD | 2.31万 SGD |
| 研究与开发 | 22.69万 SGD | 24.14万 SGD | 16.77万 SGD | 29.29万 SGD | 27.98万 SGD |
| 销售、一般及管理费用 | 439.46万 SGD | 126.93万 SGD | 83.34万 SGD | 83.04万 SGD | 24.82万 SGD |
| 营业费用 | 456.7万 SGD | 164.22万 SGD | 110.49万 SGD | 119.58万 SGD | 57.58万 SGD |
| 利息收入 | 2.66万 SGD | — | — | — | — |
| 利息支出 | 1.47万 SGD | 3.72万 SGD | 5.66万 SGD | 2017 SGD | 2783 SGD |
| 折旧和摊销 | 3.65万 SGD | 4.22万 SGD | 3.51万 SGD | 2.91万 SGD | 2.75万 SGD |
| 营业利润 | −456.76万 SGD | −164.53万 SGD | −106.83万 SGD | −117.58万 SGD | −55.28万 SGD |
| 净利润 | −467.34万 SGD | −156.05万 SGD | −111.96万 SGD | −109.45万 SGD | −51.97万 SGD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年5月27日 | 1:8 | — | — |
已生效 2026年5月27日
1:8
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
